Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Minnesota
With
National Cancer Institute (NCI)
National Institute on Drug Abuse (NIDA)
This is a randomized, multi-site trial determining the effects of switching smokeless tobacco (ST) users to lower toxicant ST products which vary in nicotine levels on biomarkers of exposure and patterns of use. ST users will undergo a two week baseline assessment period and then randomly assigned to one of three oral tobacco products (lower NNK plus NNN product with three different levels of nicotine) for a period of 8-weeks. Follow-up will occur at 9 and 20 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Using a consistent and daily amount of ST with specific nicotine and tobacco-specific nitrosamine (TSNA) levels for the past year;
2. In good physical health (no unstable medical condition);
3. Stable, good mental health (e.g., no recent unstable or untreated psychiatric diagnosis, including substance abuse, as determined by the DSM-IV criteria).
You may not be if
1. Subjects must not be currently using other tobacco or nicotine products.
